March 2024 Publications
- What is next for BCG revaccination to prevent tuberculosis? White RG, Fiore-Gartland AJ, Hanekom WA, Vekemans J, Garcia-Basteiro AL, Churchyard G, Rangaka MX, Frick M, Behr MA, Hill PC, Mave V. Lancet Respir Med. 2024 Mar. doi: 10.1016/S2213-2600(24)00009-2. Epub 2024 Jan 22.
- BCG infection dose guides dendritic cell migration and T cell priming in the draining lymph node. Krmeská V, Shen L, Nylén S, Wowk PF, Rothfuchs AG. Scand J Immunol. 2024 Mar. doi: 10.1111/sji.13342. Epub 2023 Nov 21.
- Nanotechnology of inhalable vaccines for enhancing mucosal immunity. Qin L, Sun Y, Gao N, Ling G, Zhang P. Drug Deliv Transl Res. 2024 Mar. doi: 10.1007/s13346-023-01431-7. Epub 2023 Sep 25.
- Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control. Gong W, Du J. Lancet Infect Dis. 2024 Mar. doi: 10.1016/S1473-3099(23)00514-5. Epub 2023 Nov 25.
- Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial. Wajja A, Nassanga B, Natukunda A, Serubanja J, Tumusiime J, Akurut H, Oduru G, Nassuuna J, Kabagenyi J, Morrison H, Scott H, Doherty RP, Marshall JL, Puig IC, Cose S, Kaleebu P, Webb EL, Satti I, McShane H, Elliott AM; TB042 Study Team. Lancet Infect Dis. 2024 Mar. doi: 10.1016/S1473-3099(23)00501-7. Epub 2023 Nov 25.
- OMIP-101: 27-color flow cytometry panel for immunophenotyping of major leukocyte populations in fixed whole blood. Imbratta C, Reid TD, Toefy A, Scriba TJ, Nemes E. Cytometry A. 2024 Mar. doi: 10.1002/cyto.a.24827. Epub 2024 Feb 11.
- Construction and expression of Mycobacterium tuberculosis fusion protein SHR3 and its immunogenicity analysis in combination with various adjuvants. Zhang Z, Xu L, Wang X, Kong L, Shi Z, Zhong Q, Xu Y, Wang J. Tuberculosis (Edinb). 2024 Mar. doi: 10.1016/j.tube.2024.102480. Epub 2024 Jan 23.
- Phospholipase C epsilon-1 (PLCƐ1) mediates macrophage activation and protection against tuberculosis. Gupta A, Thirunavukkarasu S, Rangel-Moreno J, et al. Infect Immun. Published online March 7, 2024. doi:10.1128/iai.00495-23
- Multiple genetic loci influence vaccine-induced protection against Mycobacterium tuberculosis in genetically diverse mice. Kurtz SL, Baker RE, Boehm FJ, Lehman CC, Mittereder LR, Khan H, Rossi AP, Gatti DM, Beamer G, Sassetti CM, Elkins KL. PLoS Pathog. 2024 Mar 7. doi: 10.1371/journal.ppat.1012069. Epub ahead of print.
- BCG-booster vaccination with HSP90-ESAT-6-HspX-RipA multivalent subunit vaccine confers durable protection against hypervirulent Mtb in mice. Kwon KW, Choi HG, Kim KS, Park SA, Kim HJ, Shin SJ. NPJ Vaccines. Published 2024 Mar 8. doi:10.1038/s41541-024-00847-7
- Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vaccine development. Chugh S, Bahal RK, Dhiman R, Singh R. NPJ Vaccines. 2024 Mar 9. doi: 10.1038/s41541-024-00834-y.
- Exploring the immunogenicity of Rv2201-519: A T-cell epitope-based antigen derived from Mycobacterium tuberculosis AsnB with implications for tuberculosis infection detection and vaccine development. Luan X, Fan X, Li G, Li M, Li N, Yan Y, Zhao X, Liu H, Wan K. Int Immunopharmacol. 2024 Mar 10. doi: 10.1016/j.intimp.2024.111542. Epub 2024 Feb 10.
- Analyzing human CD4+ T cells activated in response to macrophages infected with Mycobacterium tuberculosis. Gail DP, Suzart VG, Carpenter SM. STAR Protoc. 2024 Mar 15. doi: 10.1016/j.xpro.2024.102939. Epub 2024 Mar 6.
- Synthesis of an Immunologically Active Heptamannoside of Mycobacterium tuberculosis by the [Au]/[Ag]-Catalyzed Activation of Ethynylcyclohexyl Glycosyl Carbonate Donor. Shinde GP, Sutar Y, Kasdekar N, Joshi P, Rasool O, Ignatowicz L, Hamasur B, Hotha S. Org Lett. 2024 Mar 15. doi: 10.1021/acs.orglett.4c00175.
- Optimizing antigen selection for the development of tuberculosis vaccines. Yang Y, Chen YZ, Xia T. Cell Insight. 2024 Mar 16. doi: 10.1016/j.cellin.2024.100163.
- Immunogenicity and protective efficacy of RipA, a peptidoglycan hydrolase, against Mycobacterium tuberculosis Beijing outbreak strains. Kwon KW, Choi HG, Choi HH, Choi E, Kim H, Kim HJ, Shin SJ. Vaccine. 2024 Mar 19. doi: 10.1016/j.vaccine.2024.02.039. Epub 2024 Feb 16.
- Impact of BCG Vaccination Disruptions During the COVID-19 Pandemic on Tuberculosis Incidence in Infants: A Nationwide Study in Brazil. Procianoy GS, Cotrim MW, Cia LO, Behar PRP. J Pediatric Infect Dis Soc. 2024 Mar 19. doi: 10.1093/jpids/piae013.
- Discovering peptides and computational investigations of a multiepitope vaccine target Mycobacterium tuberculosis. Nguyen TL, Kim H. Synth Syst Biotechnol. 2024 Mar 21. doi: 10.1016/j.synbio.2024.03.010.
- Pivotal tuberculosis vaccine trial begins. Burki T. Lancet. 2024 Mar 23. doi:10.1016/S0140-6736(24)00579-8
- Rapamycin improves the long-term T-cell memory and protective efficacy of tuberculosis subunit vaccine. Niu H, Bai C, Zhu B, Zhang Y. Microb Pathog. 2024 Mar 26. doi: 10.1016/j.micpath.2024.106631. Epub ahead of print.
- Application of CRISPR-cas-based technology for the identification of tuberculosis, drug discovery and vaccine development. Shi L, Gu R, Long J, Duan G, Yang H. Mol Biol Rep. 2024 Mar 29. doi: 10.1007/s11033-024-09424-6.